The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: CCOG 0902 study

被引：0
|
作者：
Watanabe, Takuya
Nakayama, Goro
Ishigure, Kiyoshi
Hayashi, Naomi
Yaguchi, Toyohisa
Kojima, Hiroshi
Tsuboi, Kenji
Ito, Akihiro
Deguchi, Tomohiro
Sekiya, Masanori
Tanaka, Chie
Ando, Yuichi
Ohashi, Norifumi
Kodera, Yasuhiro
机构：
[1] Komaki City Hosp, Komaki, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol, Nagoya, Aichi 4648601, Japan
[3] Konan Kosei Hosp, Konan, Aichi, Japan
[4] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4648601, Japan
[5] Kainan Hosp, Yayomi, Japan
[6] Aichi Canc Ctr Hosp, Okazaki, Aichi, Japan
[7] Tosei Hosp, Seto, Japan
[8] Toki City Hosp, Toki, Gifu, Japan
[9] Tajimi Prefectual Hosp, Tajimi, Japan
[10] Nakatsugawa City Hosp, Nakatsugawa, Japan
[11] Nagoya Grad Sch Med, Nagoya, Aichi, Japan
[12] Nagoya Univ Hosp, Nagoya, Aichi, Japan
[13] Aichi Med Univ, Nagakute, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.564
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
564
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
  • [42] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Yu Hong Li
    Hui Yan Luo
    Feng Hua Wang
    Zhi Qiang Wang
    Miao Zhen Qiu
    Yan Xia Shi
    Xiao Juan Xiang
    Xiao Qing Chen
    You Jian He
    Rui Hua Xu
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 503 - 510
  • [43] Efficacy and tolerance of XELOX plus bevacizumab as first line therapy in Moroccan patients with metastatic colorectal cancer
    Tarik, Mahfoud
    Mohamed Reda, Khmamouche
    Rachid, Tanz
    Hassan, Errihani
    Mohamed, Ichou
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    R López
    M Salgado
    M Reboredo
    C Grande
    J C Méndez
    M Jorge
    C Romero
    G Quintero
    J de la Cámara
    S Candamio
    British Journal of Cancer, 2010, 103 : 1536 - 1541
  • [45] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    Lopez, R.
    Salgado, M.
    Reboredo, M.
    Grande, C.
    Mendez, J. C.
    Jorge, M.
    Romero, C.
    Quintero, G.
    de la Camara, J.
    Candamio, S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1536 - 1541
  • [46] Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)
    Nakayama, Goro
    Mitsuma, Ayako
    Sunagawa, Yuki
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Matsui, Takanori
    Nakayama, Hiroshi
    Nakata, Kazuhiko
    Ishiyama, Akiharu
    Asada, Takahiro
    Umeda, Shinichi
    Ezaka, Kazuhiro
    Hattori, Norifumi
    Takami, Hideki
    Kobayashi, Daisuke
    Tanaka, Chie
    Kanda, Mitsuro
    Yamada, Suguru
    Koike, Masahiko
    Fujiwara, Michitaka
    Fujii, Tsutomu
    Murotani, Kenta
    Ando, Yuichi
    Kodera, Yasuhiro
    ONCOLOGIST, 2018, 23 (08): : 919 - 927
  • [47] Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer
    Munoz, Alberto
    Pericay, Caries
    Garcia-Giron, Carlos
    Alonso, Vicente
    Duenas, Rosario
    Cirera, Luis
    Rivera, Fernando
    Falco, Esther
    Alvarez Bustos, Inaki
    Salud, Antonieta
    ONCOLOGY RESEARCH, 2013, 21 (04) : 181 - 191
  • [48] Bevacizumab plus capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients with metastatic colorectal cancer (mCRC) suitable for combination chemotherapy: Efficacy and safety findings from the phase II BECOX study (GEMCAD Study Group)
    Feliu, J.
    Salud, A.
    Safont, M. J.
    Garcia-Giron, C.
    Aparicio, J.
    Vera, R.
    Serra, O.
    Casado, E.
    Jorge, M.
    Maurel, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S553 - S553
  • [49] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
    Ducreux, Michel
    Bennouna, Jaafar
    Hebbar, Mohamed
    Ychou, Marc
    Lledo, Gerard
    Conroy, Thierry
    Adenis, Antoine
    Faroux, Roger
    Rebischung, Christine
    Bergougnoux, Loic
    Kockler, Leila
    Douillard, Jean-Yves
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (03) : 682 - 690
  • [50] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
12345